MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

42.96 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Jun 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
80% of Wegovy Pill Users Never Took a Weight Loss Drug Before. Does This Number Change the Entire Novo Nordisk Bear Case? ↗
Novo Nordisk could maintain this latest early-mover advantage longer than you think. 
Via The Motley Fool
News headline image
Novo's Wegovy Pill Isn't Just Beating Expectations -- It's Obliterating Them. Is the Beaten-Down Stock a Buy Now? ↗
Investors appear to have left Novo Nordisk behind as they focus on Eli Lilly; that could be a mistake. 
Via The Motley Fool
Topics Intellectual Property
News headline image
CVS Health Just Announced Fantastic News to Eli Lilly Stock Investors ↗
It's another step in Eli Lilly's quest to cement its lead in the chronic weight management market. 
Via The Motley Fool
News headline image
Eli Lilly Sees More Dealmaking Ahead as Management Looks To Leverage Its GLP-1 Success ↗
Eli Lilly knows that its GLP-1 windfall comes with an end date, so it is acting now to prepare. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Forget Zepbound: Eli Lilly's Next Billion-Dollar Weight-Loss Drug May Be Even Better ↗
Can any company pose a serious challenge to Eli Lilly in the weight-loss market? 
Via The Motley Fool
News headline image
Here's What I Think Is Really Going on With Novo Nordisk Stock ↗
There is light at the end of the tunnel. 
Via The Motley Fool
News headline image
Bull vs. Bear: The Quick Take on Viking Therapeutics Stock ↗
The pharmaceutical company's most promising drug candidate has some potential advantages over its rivals. 
Via The Motley Fool
News headline image
Eli Lilly Wins Back CVS Health, Reverting Novo's Advantage ↗
Eli Lilly and Company just secured a big win as it looks to expand GLP-1 access, mending its partnership with top pharmacy benefit manager CVS Health. 
Via MarketBeat
News headline image
Viking Therapeutics' Q3 Catalyst That Could Turn Eli Lilly's and Novo Nordisk's Daily Weight Loss Pill Strategy Upside Down ↗
An upcoming trial result could change how investors think about the weight-loss drug market. 
Via The Motley Fool
News headline image
Lexicon (LXRX) Q1 2026 Earnings Transcript ↗
Lexicon (LXRX) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Is Eli Lilly Starting an Nvidia-Style Run? ↗
Lilly shares soared more than 18% in May. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
5 Best Growth Stocks for the Next 10 Years ↗
These 5 long-term growth stocks could benefit from AI, cybersecurity, GLP-1 drugs, and fintech trends over the next decade 
Via MarketBeat
Topics Artificial Intelligence Economy
News headline image
Lilly's New Drug Just Delivered the Largest Weight Loss Ever Seen in a Clinical Trial -- Here's What It Means for Investors ↗
Eli Lilly is working on a new GLP-1 drug, and early results suggest it could be a big winner. 
Via The Motley Fool
News headline image
The Smartest Growth Stocks to Buy With $2,000 Right Now ↗
Most of the market's best-known growth names are overbought at this time. That's not the case for several off-the-radar alternatives. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Stock Split Watch: Is Eli Lilly Next? ↗
Lilly has split its stock in the past. 
Via The Motley Fool
News headline image
Contrarian Opinion: Novo Nordisk Is A Better Buy Than Eli Lilly Right Now ↗
Novo Nordisk lost its lead in the GLP-1 race, but Eli Lilly's valuation is a bit rich. 
Via The Motley Fool
News headline image
Hims & Hers Eyes Global Growth: Will $1.15B Eucalyptus Deal Fuel Its Recovery or Dilute Shareholders? ↗
Hims & Hers is acquiring Australian telehealth platform Eucalyptus as part of its international expansion plan while using $350 million in convertible senior notes. 
Via MarketBeat
Topics Earnings
News headline image
Novo Nordisk Is Beating Eli Lilly in the Obesity Pill Market. Should Lilly Investors Be Worried? ↗
There is no reason to panic just yet. 
Via The Motley Fool
News headline image
President Trump Loaded Up on Eli Lilly in Q1. Should You Buy the Obesity Drug Stock Too? ↗
Eli Lilly's fundamentals matter more than Trump's stock purchases. 
Via The Motley Fool
Topics Government
News headline image
Prediction: These 2 Obesity Drug Stocks Could Double in 2026 ↗
These players are seeing exciting results in clinical trials. 
Via The Motley Fool
News headline image
Don't Buy Viking Therapeutics Stock Until You Read This ↗
It may be too late for Viking to take on the "dark horse" role in the GLP-1 wars. 
Via The Motley Fool
News headline image
Eli Lilly Just Got a Huge Vote of Confidence From Morgan Stanley -- and It's All About Mounjaro ↗
The efficacy of Eli Lilly's new, still-in-development GLP-1 drug is gaining attention, but don't forget its older GLP-1 drugs just yet. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Eli Lilly Just Made a Game-Changing Move in the Billion-Dollar Weight Loss Drug Space. Here's What You Need to Know. ↗
The pharma giant is taking steps to expand its portfolio. 
Via The Motley Fool
News headline image
The Silver Lining of Last Week's Hims & Hers Earnings Miss ↗
Hims & Hers plunged 23% after a major Q1 earnings miss, but long-term growth stays intact via its Novo Nordisk GLP-1 partnership and a late 2026 expansion. 
Via MarketBeat
Topics Earnings
News headline image
Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(NYSE:MMA),(NYSE:NVO),(NYSE:HIMS),(NYSE:LLY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Government
News headline image
Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
Analysts project billions in future market value as biotech innovation and consumer demand continue driving the next wave of health performance products 
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
Could Viking Therapeutics Be the Next Eli Lilly? ↗
Demand for weight loss drugs may fuel growth for more than one player. 
Via The Motley Fool
News headline image
Best Weight Loss Drug Stocks to Buy in 2026 ↗
If you are looking for a GLP-1 investment, you can buy the leader, the underdog, or the upstart. 
Via The Motley Fool
Topics Intellectual Property
News headline image
From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook ↗
Eli Lilly just got more good news, posting promising results for its oral GLP-1 as the firm looks to unlock new sources of demand. 
Via MarketBeat
News headline image
Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics' Pill Could Crash the Weight-Loss Party ↗
This dark horse in the weight loss drug race is worth keeping on your watch list. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story